Last update :
08/05/2024
Vasodilator   Alprostadil  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Alfaprostin Egypt
Alistint Peru
Alpros Turkey
Alprostadil Argentina, Canada, Chile, Ecuador, Germany, Malaysia, Peru, Romania, Spain, Turkey, United States of America
Alprostapint Argentina, Austria, Colombia, Ecuador, Hungary, Peru
Alprostar Italy
Aplicav Brazil
Cardiobon Argentina, Peru
Caverject Austria, Belgium, Brazil, Canada, Denmark, France, Great Britain, Italy, Norway, Poland, Portugal, Republic of South Africa, Slovenia, Spain, Sweden, Switzerland, Turkey, United States of America
Edex France
Liple Japan
Minprog Austria, Germany
Ostapint Mexico, Peru
Palux Japan
Pridax Austria, Germany, Romania, Spain
Prolisina VR Argentina
Prostandin Japan
Prostavasin Austria, Egypt, Germany, Hungary, Iran, Italy, Luxembourg, Poland
Prostin VR Australia, Belgium, Canada, Denmark, Finland, Great Britain, Greece, Hungary, Iran, Italy, Luxembourg, Malaysia, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Switzerland, United States of America, Venezuela
Prostine VR France
Vasaprostan Romania
Stability of mixtures   Injection   Stability of mixtures : Alprostadil     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass NaCl 0,9% + antibacterial 12,5 µg/ml
Injection   Alprostadil   
Injection   Papaverine hydrochloride 4,5 mg/ml
Injection   Phentolamine mesylate 0,125 mg/ml
-20°C
180 Day
Protect from light 1899
Level of evidence A
Glass NaCl 0,9% + antibacterial 12,5 µg/ml
Injection   Alprostadil   
Injection   Papaverine hydrochloride 4,5 mg/ml
Injection   Phentolamine mesylate 0,125 mg/ml
4°C
30 Day
Protect from light 1899
Level of evidence A
Polypropylene Sodium chloride 0,9% 15 µg/ml
Injection   Alprostadil   
Injection   Papaverine hydrochloride 15 mg/ml
Injection   Urapidil 2 mg/ml
2-8°C
55 Day
Protect from light 3448
Level of evidence B

  Mentions Légales